Rua Bioscience advises that it has reached a settlement with Cann Group Limited (ASX:CAN), following legal proceedings initiated by Rua in February 2024.
As part of the legal proceedings, both parties undertook mediation which had led to this settlement. Rua Bioscience and Cann Group have executed new supply agreements to support their respective operations in the New Zealand and Australian medicinal cannabis markets. The commercial terms of the settlement are confidential and take effect immediately.
ENDS
The person who authorised this announcement:
Paul Naske
Chief Executive Officer
[email protected]
+64 21 445154
Executive chair Keith Jackson says the firm is not concerned.
New Zealand shares ended firmer after Infratil and Spark posted gains.
The case was a first for New Zealand courts, FMA says.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details